Fresenius Locks In EUR 523 Million From FMC Stake Sale as Analysts Rush to Raise Targets

Fresenius has found no shortage of takers for its latest slice of Fresenius Medical Care. The placement of roughly 13.4 million FMC shares, announced a day earlier, was multiple times oversubscribed at the indicated price of EUR 39 per share, according to Handelsblatt. The sale is expected to raise just under EUR 523 million, cash the group intends to channel into its growth platforms.

The pricing carried a 4.4% discount to FMC's previous Xetra close. Final terms and allocations were due to be published before the start of Xetra trading, leaving the confirmed conditions as the next item on the agenda. Demand of that scale points to the absorption capacity of the institutional market for a block of this size — provided the indicated price holds.

Stake Trimmed From 25% to 20%

The accelerated bookbuilding process, aimed squarely at institutional investors, will cut Fresenius's holding from around 25% to roughly 20% of FMC. The package on offer equates to about 5% of FMC's issued share capital. It marks a further step in the gradual unwinding of the stake, which Fresenius has carried as a financial investment since deconsolidation on 30 November 2023.

A 90-day lock-up applies to the remaining shares, subject to customary market exceptions, capping any further sales of the residual position for now. Fresenius stays on the FMC register once the transaction settles as planned. The move follows an earlier sale of FMC stock for EUR 300 million in August 2026.

Should investors sell immediately? Or is it worth buying Fresenius?

CEO Michael Sen has framed the disposal as a means of freeing up room for the group's growth platforms, with net proceeds to be deployed in line with the capital allocation priorities of #FutureFresenius. For investors, the test lies less in the sale itself than in where the money lands — and what it delivers once invested.

Jefferies Lifts Target to EUR 62

Sentiment around the equity got a separate boost on Monday, when Jefferies raised its price target on Fresenius from EUR 55 to EUR 62 while reaffirming its "Buy" rating. The analysts pointed to the quarterly report and the agreement with WuXi Biologics. Two other research houses lifted their targets to EUR 58 and EUR 58.50 respectively the same day, both keeping positive ratings. The shares nonetheless slipped 1.1% in today's trading.

The bullish case rests on upgraded guidance and a widening pipeline. On 4 November, Fresenius raised its full-year outlook: the group EBIT margin is now expected above 11.5%, compared with around 11.5% previously, while currency-adjusted growth in core earnings per share is seen in the upper half of the 10–15% range. In the third quarter of 2026, group EBIT reached EUR 638 million, a currency-adjusted gain of 10%, with Kabi and Helios underpinning the result.

Fresenius at a turning point? This analysis reveals what investors need to know now.

Biosimilar Pipeline Set to Double

The collaboration agreed with WuXi Biologics on 2 November gives Fresenius exclusive access to up to 37 potential biosimilar candidates. That could expand its portfolio from 29 to as many as 66 molecules over the coming decade. Fresenius secures worldwide exclusive marketing rights for selected products, while WuXi Biologics handles development work on a fee basis.

Alongside the pipeline news, Fresenius Kabi disclosed the theft of individual packs of its Idacio and Tyenne biosimilars. Distributor IMP International Medical Products has issued a precautionary recall of the affected packs — individual units rather than whole batches — because transport and storage conditions can no longer be verified, meaning quality and integrity cannot be guaranteed.

Ad

Fresenius Stock: New Analysis - 12 November

Fresh Fresenius information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated Fresenius analysis...